Sera Prognostics (NASDAQ:SERA) CFO Sells $15,905.28 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 5,232 shares of Sera Prognostics stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $3.04, for a total value of $15,905.28. Following the completion of the sale, the chief financial officer directly owned 273,087 shares in the company, valued at $830,184.48. This represents a 1.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Austin Aerts also recently made the following trade(s):

• On Thursday, September 11th, Austin Aerts sold 915 shares of Sera Prognostics stock. The stock was sold at an average price of $3.13, for a total value of $2,863.95.

Sera Prognostics Stock Performance

Sera Prognostics stock traded up $0.33 during midday trading on Wednesday, reaching $3.40. The stock had a trading volume of 121,326 shares, compared to its average volume of 29,844. The stock has a market capitalization of $131.24 million, a P/E ratio of -4.42 and a beta of 0.97. The firm’s fifty day simple moving average is $3.18 and its 200-day simple moving average is $2.79. Sera Prognostics, Inc. has a 1-year low of $1.37 and a 1-year high of $9.13.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.03. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.10 million. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 41.69%. On average, sell-side analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on SERA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday. Wall Street Zen upgraded Sera Prognostics from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Sera Prognostics has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Abel Hall LLC bought a new stake in shares of Sera Prognostics in the 2nd quarter valued at about $31,000. Wagner Wealth Management LLC acquired a new position in Sera Prognostics during the second quarter worth approximately $34,000. Riverview Capital Advisers LLC bought a new stake in Sera Prognostics in the second quarter valued at approximately $35,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Sera Prognostics in the third quarter valued at approximately $38,000. Finally, XTX Topco Ltd bought a new position in shares of Sera Prognostics during the 1st quarter worth approximately $39,000. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.